Anixa Biosciences has presented final Phase 1 findings from its investigational alpha-lactalbumin breast cancer vaccine, which generated protocol-defined immune responses in 74% of participants, alongside survival observations from the ongoing Phase 1 trial of liraltagene autoleucel, or lira-cel, in recurrent ovarian cancer. The two clinical-stage immunotherapy programmes, developed with Cleveland Clinic and Moffitt Cancer Center respectively, were discussed at the New York Academy of Sciences Frontiers in Cancer Immunotherapy symposium as Anixa prepares the vaccine for Phase 2 development and continues dose escalation of the CAR-T therapy.
Why does a 74% immune response matter when breast cancer prevention remains unproven?
The most important achievement from the completed vaccine study is not evidence that the product prevents breast cancer. It is evidence that the alpha-lactalbumin antigen can be administered at a tolerable dose and stimulate a measurable immune response in a majority of participants. Establishing those two features was the central task of the Phase 1 programme, and the result gives Anixa Biosciences a biologically credible basis for advancing into efficacy testing.
The study enrolled 35 participants across three clinically different groups. These included patients previously treated for early-stage triple-negative breast cancer who remained at elevated risk of recurrence, cancer-free participants with inherited risk factors who were planning preventive mastectomy, and patients with residual disease who received the vaccine alongside pembrolizumab following earlier treatment. Participants received three vaccinations at two-week intervals, while investigators assessed cellular and antibody responses and monitored tolerability.
The maximum tolerated dose produced mainly low-grade injection-site reactions, an encouraging feature for a product that may eventually be tested in people who do not have active cancer. Preventive medicines face an unusually strict safety threshold because recipients may otherwise be healthy, and even modest systemic toxicity can become difficult to justify when the clinical benefit remains years away.
However, immune activation is a pharmacodynamic result, not a clinical outcome. A protocol-defined T-cell response does not establish that the immune system can eliminate microscopic disease, delay recurrence or prevent a new tumour from developing. The central Phase 2 question is therefore whether the observed immune response is sufficiently strong, durable and tumour-directed to alter the course of triple-negative breast cancer.
What does the alpha-lactalbumin target reveal about Anixa’s preventive vaccine strategy?
The scientific logic of the programme rests on what researchers describe as a retired-protein strategy. Alpha-lactalbumin is normally associated with breast tissue during lactation and is generally absent after lactation ends, but the protein reappears in a substantial proportion of triple-negative breast cancers. Vaccination is intended to train the immune system to recognise cells expressing that protein before an emerging tumour becomes clinically established.
This approach is distinct from preventive cancer vaccines directed against infectious causes such as human papillomavirus or hepatitis B virus. Anixa Biosciences is attempting to vaccinate against a human protein that becomes abnormally expressed in malignant tissue. That creates an opportunity for more direct tumour prevention, but it also introduces questions about tissue selectivity, antigen expression and the possibility of immune effects in normal breast tissue under certain physiological conditions.
The programme may ultimately be most relevant for individuals with inherited mutations that materially increase the risk of triple-negative breast cancer. Current risk-reduction strategies for these individuals can involve intensive surveillance and preventive surgery. A vaccine capable of lowering cancer risk without major surgery would represent a significant clinical advance, but such a claim would require large studies, long follow-up periods and convincing evidence that protection persists over time.
The target is also unlikely to be universally relevant. Alpha-lactalbumin expression varies among tumours, and preliminary tissue analysis has shown expression ranging from absent to strong. A future clinical programme may therefore need a biomarker strategy to identify patients whose tumours, residual disease or underlying risk profile make them more likely to benefit.
Why is a therapeutic Phase 2 trial more practical than an immediate prevention study?
Although prevention remains the programme’s most ambitious long-term goal, Anixa Biosciences is preparing to test the vaccine in a therapeutic setting first. The planned Phase 2 study is expected to focus on patients with newly diagnosed breast cancer, potentially allowing vaccination before surgery and enabling investigators to examine immune activity, tumour tissue and pathological response within a manageable timeframe.
This design can generate evidence more quickly than a pure prevention trial involving healthy high-risk participants. A definitive prevention study would need to enrol many individuals and follow them for years to determine whether the incidence of breast cancer falls. A neoadjuvant study can instead evaluate biological activity inside the tumour, changes in immune-cell infiltration and potential improvements in pathological response after a shorter treatment period.
The approach also creates a bridge between the immune-response findings from Phase 1 and the distant goal of cancer prevention. Demonstrating that vaccine-induced immune cells can enter tumours and contribute to tumour reduction would make the preventive hypothesis more credible. Failure to show meaningful intratumoral activity, however, would weaken the argument that circulating immune responses are clinically relevant.
Manufacturing has become another important development test. Anixa Biosciences has selected Cytovance Biologics to produce clinical-grade material for Phase 2. Moving from investigator-led early research into a larger sponsored trial requires reproducible antigen production, validated potency testing, batch consistency and a formulation capable of supporting additional sites. Manufacturing delays or changes that alter immune activity could affect the Phase 2 timetable and complicate comparisons with Phase 1.
How should the lira-cel survival observations in recurrent ovarian cancer be interpreted?
The lira-cel programme addresses a different clinical problem and uses a substantially more complex therapeutic platform. Liraltagene autoleucel is an autologous cell therapy engineered to target the follicle-stimulating hormone receptor, or FSHR, in patients with recurrent ovarian cancer who have progressed after multiple previous treatments.
Several treated patients have lived for more than one year after receiving lira-cel, while one participant survived for 28 months. These observations are notable because the enrolled population had advanced, heavily pretreated disease and few remaining therapeutic options. The absence of major early safety complications has also allowed investigators to continue exploring higher cell doses.
Nevertheless, the survival figures remain descriptive observations from a small, uncontrolled Phase 1 study. They do not establish that lira-cel caused the longer survival. Patients entering an early-stage cell therapy trial can differ significantly in disease burden, tumour biology, previous treatment, performance status and access to subsequent therapies. Comparing individual outcomes with an estimated survival expectation cannot substitute for a prospectively defined control group or a robust historical comparison.
The current dataset also provides limited information about objective tumour responses, progression-free survival and response durability. Survival can be influenced by several factors unrelated to direct tumour reduction. Future updates will become more informative if they show measurable tumour shrinkage, prolonged disease control, CAR-T expansion, persistence within the body and a consistent relationship between treatment exposure and clinical outcome.
What does the early safety profile enable for intraperitoneal ovarian CAR-T therapy?
Lira-cel has not produced dose-limiting toxicities in the initial dose cohorts, and investigators have not reported significant cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome in those groups. This differentiates the early experience from the systemic toxicities commonly associated with some CAR-T therapies used in blood cancers, although the number of treated patients remains too small to define the full risk profile.
The therapy is delivered directly into the peritoneal cavity, where ovarian cancer frequently spreads. Local delivery may increase exposure around tumour deposits while limiting systemic circulation, potentially improving the balance between activity and toxicity. It also represents a logical attempt to overcome one of the major barriers facing cell therapies in solid tumours, namely the difficulty of delivering enough functional T cells to multiple tumour sites.
The clean early safety data have enabled a substantial dose-escalation strategy and the introduction of lymphodepleting chemotherapy before treatment. Cyclophosphamide and fludarabine are intended to reduce competing immune cells and create conditions that support CAR-T expansion and persistence. This preparatory approach is established in blood cancer cell therapy, but its role in solid tumours remains less certain.
Dose escalation will clarify whether earlier cohorts received too few active cells to produce consistent antitumour effects. It may also introduce toxicity that was not visible at lower doses. Lymphodepletion further changes the treatment regimen, making it harder to compare future outcomes directly with those of patients treated without preparatory chemotherapy.
Why is FSHR an attractive but still unvalidated target for solid-tumour cell therapy?
The follicle-stimulating hormone receptor is expressed on ovarian tissue, tumour-associated blood vessels and some ovarian cancer cells, while having relatively limited distribution across other normal tissues. Lira-cel uses a chimeric endocrine receptor that incorporates the natural FSH ligand to recognise FSHR, rather than relying on the antibody-derived binding structure commonly used in conventional CAR-T designs.
Targeting both malignant cells and the blood vessels supporting a tumour could theoretically provide a broader mechanism of action. Damaging tumour vasculature may restrict nutrient delivery and create secondary antitumour effects even when receptor expression varies across cancer cells. The ligand-based receptor design may also offer different binding characteristics from antibody-based CAR constructs.
The challenge is that target expression alone does not ensure therapeutic success. Solid tumours can display uneven antigen density, suppress immune-cell function and create physical barriers that prevent engineered T cells from reaching all disease sites. T cells can also become exhausted or disappear before producing durable control. The clinical programme will need to determine whether FSHR expression predicts response and whether intraperitoneally administered cells remain active long enough to influence survival.
Investigators will also need to understand whether tumour cells can evade treatment by reducing FSHR expression. A therapy directed against a single target can select for cells that lack that target, allowing resistant disease to expand. Tissue studies and serial biomarker testing could therefore become as important as dose selection.
What does the dual-program update mean for Anixa Biosciences’ development strategy?
Presenting both programmes together highlights a pipeline built around institutional partnerships rather than a conventional internal research organisation. Cleveland Clinic developed the vaccine technology, while Moffitt Cancer Center is leading the ovarian cancer cell therapy work. This structure provides access to specialised scientific expertise and clinical infrastructure, allowing Anixa Biosciences to advance programmes that would otherwise require substantial internal capabilities.
The model can reduce early research expenditure, but it does not remove later-stage execution risk. As programmes progress, Anixa Biosciences will need to fund clinical manufacturing, regulatory work, larger multicentre trials and increasingly complex data systems. The breast cancer vaccine and lira-cel also require different manufacturing platforms, clinical operations and regulatory strategies.
Running two high-risk oncology programmes offers diversification, since progress in one programme can offset delays in the other. It can also divide capital and management attention. The breast cancer vaccine has a clearer near-term route into Phase 2, while lira-cel remains in dose escalation and has not yet produced a conventional efficacy dataset. Capital allocation decisions may become more difficult as both programmes approach costlier development stages.
The partnerships also create economic obligations through licensing and potential royalties. Those arrangements are normal for institution-originated biotechnology assets, but they can influence future partnership negotiations and commercial economics. A larger pharmaceutical partner may eventually be needed if either programme generates sufficiently strong clinical evidence.
What evidence will clinicians and regulators need from the next trial updates?
For the breast cancer vaccine, the next meaningful milestone will be the Phase 2 protocol rather than another presentation of the Phase 1 immune-response rate. Clinicians will want to know which patients will be enrolled, whether alpha-lactalbumin expression will guide selection, how the vaccine will be combined with standard therapy and which endpoint will determine whether the trial has succeeded.
Investigators will also need to connect immune-response measurements with tumour-level activity. A higher T-cell response is valuable only if it correlates with improved pathological response, delayed recurrence or another clinically meaningful outcome. Durability will matter because preventive immune protection may need to last for years rather than months.
For lira-cel, the next higher-dose cohorts will be critical. The programme needs evidence that lymphodepletion and increased cell dosing improve expansion, persistence and antitumour activity without producing unacceptable toxicity. Objective response rates, duration of response, progression-free survival and detailed biomarker findings would make the survival observations easier to interpret.
The symposium presentations therefore strengthen both programmes without resolving their central uncertainties. Anixa Biosciences has shown that its breast cancer vaccine can activate the intended immune response and that lira-cel can be delivered with an encouraging preliminary safety profile. The next stage must show whether those biological signals can become reproducible clinical benefits.
Can Anixa’s breast cancer vaccine and lira-cel CAR-T therapy translate early immune signals into clinical benefit? added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →